← Back to Search

Selective Serotonin Reuptake Inhibitor

Escitalopram for Obsessive-Compulsive Disorder

Phase 4
Waitlist Available
Led By Martine F. Flament, MD
Research Sponsored by University of Ottawa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up each study visit
Awards & highlights

Study Summary

Although research suggests that patients with obsessive-compulsive disorder (OCD) exhibit specific deficits in their high cognitive processes, it is still unknown how these deficits relate to the clinical symptoms of the disorder, and to the response to treatment. There are two aims for the proposed research. The first is to examine how high cognitive processes and brain activity are affected in OCD. The second aim is to investigate the effects of a specific psychotropic medication (escitalopram) on high cognitive processes and brain activity in OCD. We will investigate how 40 youth with OCD (recruited in specialized clinics) differ from 40 healthy youth (recruited from the local community) on selected cognitive tests and brain imaging paradigms, as well as explore how treatment with medication can correct or reverse the observed differences. The final goal of our research is to learn more about the mechanisms of action for available treatments, in order to refine and improve short- and long-term therapeutic strategies for a highly debilitating and often lifelong disorder.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after treatment and at each study visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after treatment and at each study visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Children's Yale-Brown Obsessive Compulsive Scale score.
Secondary outcome measures
Clinical Global Impression for Severity of Illness and Improvement

Side effects data

From 2019 Phase 4 trial • 115 Patients • NCT01902004
23%
Sleepiness/Sedation
10%
Headache
8%
Tension/Inner Unrest
8%
Reduced Salivation
8%
Concentration Difficulties
8%
Diminished Sexual Drive
6%
Asthenia/Lassitude/Increased Fatigability
6%
Constipation
6%
Polyuria/Polydipsia
6%
Orthostatic Dizziness
4%
Nausea/Vomiting
4%
Erectile Dysfunction
4%
Failing Memory
2%
Diarrhea
2%
Increased Duration of Sleep
2%
Reduced Duration of Sleep
2%
Increased Dream Activity
2%
Accomodation Disturbance
2%
Increased Tendancy to Sweating
2%
Weight Gain
2%
Ejaculatory Dysfunction
2%
Micturtion Disturbances
100%
80%
60%
40%
20%
0%
Study treatment Arm
Escitalopram and Placebo
Escitalopram and Memantine

Trial Design

1Treatment groups
Experimental Treatment
Group I: EscitalopramExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Escitalopram
FDA approved

Find a Location

Who is running the clinical trial?

University of OttawaLead Sponsor
208 Previous Clinical Trials
267,116 Total Patients Enrolled
H. Lundbeck A/SIndustry Sponsor
325 Previous Clinical Trials
77,543 Total Patients Enrolled
Martine F. Flament, MDPrincipal InvestigatorUniversity of Ottawa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby May 2025